EARS - Auris Medical Holding Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.6700
+0.0300 (+1.14%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.6400
Open2.6800
Bid0.0000 x 900
Ask0.0000 x 2200
Day's Range2.5900 - 2.7300
52 Week Range2.4100 - 39.4000
Volume48,395
Avg. Volume198,107
Market Cap8.724M
Beta (3Y Monthly)-0.19
PE Ratio (TTM)N/A
EPS (TTM)-1.3270
Earnings DateAug 15, 2019 - Aug 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.41
Trade prices are not sourced from all markets
  • GlobeNewswire

    Auris Medical Provides Business Update and Reports First Half 2019 Financial Results

    Hamilton, Bermuda, Aug. 15, 2019 -- Enrollment of first patient in TRAVERS Phase 2 trial with AM-125 in acute vertigoEnrollment completed in Phase 1b trial with AM-201 in.

  • GlobeNewswire

    Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo

    The TRAVERS trial will enroll a total of 138 patients who suffer from acute vertigo following surgical removal of a vestibular schwannoma, a tumor growing behind the inner ear. In addition, oral betahistine 48 mg will be tested in 16 patients under open-label conditions for reference. “After securing approvals from the numerous regulatory authorities and ethics committees involved, we are excited to start patient enrollment into the TRAVERS trial,” commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO.

  • GlobeNewswire

    Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

    The trial enrolled in total 50 healthy volunteers who received either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks. “Completing enrollment for this proof-of-concept study is another important step forward with our AM-201 development program,” commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “Excessive weight gain and somnolence are major side effects of antipsychotic drugs that frequently have a major impact on patient well-being and quality of life.

  • Savara Plunges on Failure of Late-Stage Study on Molgradex
    Zacks

    Savara Plunges on Failure of Late-Stage Study on Molgradex

    Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

  • GlobeNewswire

    Auris Medical Holding Ltd Provides Corporate Update

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today provided a business update, including a review of recent clinical, regulatory and operational highlights and progress. “In the past few months, we continued to make substantial progress with our intranasal betahistine development program, moving into two proof-of-concept studies,” stated Thomas Meyer, Auris Medical’s founder, Chairman and CEO.

  • GlobeNewswire

    Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders (the “Company”), announced today that it has received written notification from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (“Nasdaq”).. The Panel determined that the Company is in compliance with all applicable Nasdaq listing standards, that its common shares will continue to be listed on Nasdaq and that the Panel considers this matter closed. Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care.

  • GlobeNewswire

    Auris Medical Announces Closing of Public Offering of Common Shares

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today the closing of its previously announced underwritten public offering of: (i) 440,000 common shares together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option. The combined public offering price per unit of one common share and one warrant to purchase one common share is $3.90 and $3.89 per unit of one pre-funded warrant to purchase one common share and one warrant to purchase one common share.

  • GlobeNewswire

    Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the successful closing of the purchase of two US patents related to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD). The Company acquired full ownership of the US patents 8,119,668 and 8,242,148, “Treatment methods employing histamine H3 receptor antagonists, including betahistine,” with key claims directed towards the treatment of depression and ADHD, respectively.

  • GlobeNewswire

    Auris Medical Holding Ltd.:

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today the pricing of an underwritten public offering of: (i) 330,000 common shares together with warrants to purchase 330,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares. The combined public offering price per common unit is $3.90 and $3.89 per pre-funded unit.  The pre-funded warrants will have an initial per share exercise price of CHF 0.01, are exercisable immediately and will expire when exercised in full.  The common share warrants will have an initial per share exercise price of CHF 4.34, subject to customary adjustment, are exercisable immediately and will expire 5 years from the date of issuance.

  • GlobeNewswire

    Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

    The Phase 1b trial with AM-201 is being conducted at one European site. The trial will enroll in total 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks. The protocol is based on a dose escalation with five different doses of intranasal betahistine.

  • GlobeNewswire

    Auris Medical Announces Reverse Stock Split

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20. The reverse stock split is expected to become effective on May 1, 2019, and the shares to begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "EARS". The new CUSIP number following the reverse stock split will be G07025201.

  • GlobeNewswire

    Auris Medical Provides Update on Tinnitus Drug Development Strategy

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today provided an update on its tinnitus drug development strategy. The Company intends to discuss and validate the protocol for a pivotal clinical trial with its late-stage investigational drug Keyzilen® (AM-101) with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and to take the program forward through partnering or other types of non-dilutive funding. The Company has completed the design of a new Phase 2/3 trial for its late-stage Keyzilen® program.

  • Benzinga

    Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

    Zoom Technologies Inc (OTC: ZOOM ) traded higher by as much as 120 percent Thursday morning after popular video and audio platform Zoom Video Communications Inc (NASDAQ: ZM ) held its highly anticipated ...

  • GlobeNewswire

    Auris Medical Receives Positive Nasdaq Listing Determination

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the Nasdaq Hearings Panel (the ''Panel'') has granted the Company’s request for the continued listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”). The Company’s continued listing on Nasdaq is subject to the Company evidencing compliance with the minimum $1.00 bid price requirement on or before August 5, 2019. At the hearing before the Panel, the Company presented its plan to regain compliance with the minimum bid price requirement, including the implementation of a reverse stock split if necessary.

  • GlobeNewswire

    Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first cohort of subjects have been randomized in its Phase 1b proof-of-concept trial of AM-201, the Company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence. The Phase 1b trial with AM-201 is being conducted at one European site. The trial will enroll in total 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks.

  • GlobeNewswire

    Auris Medical Announces 20-F Filing

    March 14, 2019 - Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission. Upon request, Auris Medical will send a copy of the Annual Report to any requesting shareholder. Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.

  • ACCESSWIRE

    These Four Healthcare Stocks Could Test March Highs

    Given that the success of the healthcare industry is dependent on companies meeting the demands of patients who simply want to live healthy lives, any company taking a patient-centric focus to their healthcare framework has seen impressive gains in the first few months of 2019. Investors looking for potential opportunities could benefit from keeping tabs on the healthcare industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Hancock Jaffe Laboratories Inc (HJLI), Kitov Pharmaceuticals Ltd (KTOV), and Auris Medical Holding AG (EARS) are 4 healthcare companies heating up on Thursday.

  • Associated Press

    Auris: 4Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 12 cents. For the year, the company reported that its loss narrowed to $11.8 million, or 74 cents per share. The company's ...

  • GlobeNewswire

    Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards.

  • GlobeNewswire

    Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the publication of an article that presents and discusses in detail the outcomes from the HEALOS Phase 3 trial with AM-111, Auris Medical's investigational treatment for acute inner ear hearing loss. The peer-reviewed article "Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness - A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study" was published in Otology & Neurotology, one of the leading journals in the field of scientific and clinical inner ear research. "The HEALOS trial demonstrated that effective hearing protection is possible with a drug-based approach even in the case of profound acute hearing loss, a condition with very poor prognosis for recovery and high risk for life-long auditory and cognitive disability," commented Hinrich Staecker, MD, PhD, Professor, Department of Otolaryngology Head and Neck Surgery, University of Kansas Medical Center, Kansas City, lead author on the publication.

  • GlobeNewswire

    Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019

    Zug, Switzerland, March 07, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.

  • GlobeNewswire

    Auris Medical Announces Receipt of Nasdaq Notice

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced its receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company did not meet Nasdaq's January 28, 2019 deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2) due to the bid price per share for its common shares remaining below $1.00. Further, Nasdaq determined that the Company was not eligible for a second 180 day period to regain compliance since the Company did not comply with the $5,000,000 Stockholders' Equity initial listing requirement for The Nasdaq Capital Market. The Notice states that, unless the Company requests an appeal, Nasdaq intends to suspend the Company's common shares and remove them from listing and registration on Nasdaq.

  • GlobeNewswire

    Auris Medical Announces Full Repayment of Hercules Loan Facility

    On July 19, 2016, the Company had entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. ("Hercules") and drawn $12.5 million under the facility. On January 31, 2019, the Company made the final payment to Hercules under the facility, comprising the last amortization rate as well as an end of term charge, 12 months ahead of the original schedule. With the final payment, all covenants and collaterals in favor of Hercules have been lifted.

  • GlobeNewswire

    Auris Medical to Redomicile Holding Company from Switzerland to Bermuda

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced its intention to relocate the Company's domicile from Zug, Switzerland to Hamilton, Bermuda. With the redomiciliation, the Company expects to gain more corporate flexibility, achieve cost savings and operate under a jurisdiction that is more familiar to U.S. investors.